Source link : https://newshealth.biz/health-news/pegcetacoplan-maintains-kidney-benefits-at-52-weeks/
Pegcetacoplan, a targeted C3/C3b inhibitor, shows sustained, robust effects on key markers of kidney disease in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), according to 52-week results from the VALIANT trial. The 26-week results, which were presented last October at Kidney Week 2024, showed a highly significant difference in change in […]
The post Pegcetacoplan Maintains Kidney Benefits at 52 Weeks first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-08 00:40:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8